AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Q4 2015 Earnings Presentation

30 slides from AMAG Pharmaceuticals's earnings presentation, Feb 17, 2016

  1. Slide 1: Forward-looking statements

    This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including among others, statements regarding expected 2015 finan

  2. Slide 2: 4Q 2015 Earnings Call Agenda

    4Q 2015 Earnings Call Agenda Transformational Growth 1 2 3 4 2016 Key Priorities and Closing Remarks 5 Q&A 5 Commercial Performance and Developments 4Q 2015 Results and Financial Update

  3. Slide 3: 2015 In Review

    2015 In Review Solid financial performance1 Makena sales +52% from 2014 pro forma revenue Adjusted EBITDA increased to $213.4 MM, compared with $14.3 MM in 2014 Non-GAAP diluted EPS increased to $4.43, compared with $0.30 in 2014 Expanded portfolio and advanced pipeline development programs Acquired

  4. Slide 4: 4Q/FY 2015 Financial Results

    Copyright © 2015 AMAG Pharmaceuticals. All Rights Reserved. 4Q/FY 2015 Financial Results

  5. Slide 5: 4Q 2015 – Finished the Year Strong

    4Q 2015 – Finished the Year Strong Non-GAAP Revenue1 ($ MM) Non-GAAP Adjusted EBITDA1 ($ MM) Non-GAAP Diluted EPS1 ($/share) Grew non-GAAP revenue 137% and adjusted EBITDA 322% Exited 2015 with $466.3 MM in cash & investments and 34.7 MM basic shares outstanding Total net leverage ratio ~2.4x annual

  6. Slide 6: Full Year 2015 Financial Summary GAAP to Non-GAAP Comparison

    Full Year 2015 Financial Summary GAAP to NON-GAAP Comparison1 1 Unaudited. See slides 23-25 for a reconciliations of GAAP to non-GAAP financial information. 2 See slide 27 for share reconciliation. ($ in millions, except per share data) 2015 (GAAP) Adjustments 2015 (Non-GAAP) Total revenues $418.3 $

  7. Slide 7: Full Year 2015 Financial Summary GAAP to Non-GAAP Comparison

    GAAP TO NON-GAAP COMPARISON! Gam ag Full Year 2015 Financial Summary 2015 $ in millions, except per share data ( pt p ) (GAAP) Adjustments 2015 (Non-GAAP) Total revenues $418.3 $20.8 Cost of revenue 88.5 (66.1) Gross margin $329.8 $45.2 Operating expenses 218.6 (57.0) Operating income / Adjusted EBI

  8. Slide 8: Makena Recent Accomplishments and Future Growth Drivers

    Recent Accomplishments and Future Growth Drivers: Increased 4Q15 market share to 35%, up from 24% in 4Q14 Continue to pull through recent formulary wins Maternal health sales force increased to 104 reps from 76 reps (+37%) ~60% of Makena patients are processed through Makena Care Connection and/or f

  9. Slide 9: Executing on Makena Next Generation Development Programs

    Executing on Makena Next Generation Development Programs Makena longer-acting formulation Pre Feb 2018 Post Feb 2018 Preservative free More convenient for HCPs More cost effective for insurers In vivo feasibility established Less frequent injections More convenient for patient and HCP Provides oppor

  10. Slide 10: Significant Decrease in Needle Size

    Significant Decrease in Needle Size 11 Makena IM1 Injection vs. subcutaneous injection Makena currently injected with large 21 gauge needle into the muscle Advantage of auto-injector is that it allows for subcutaneous administration of Makena Specifically designed for administration of viscous mater

  11. Slide 11: Favorable Physician Response to Makena Next Generation Products

    Favorable Physician Response to Makena Next Generation Products Physician’s Therapy Preferences Makena is the therapy of choice for at-risk women Respondents state that Makena is administered ~70% in-office, while ~30% administered at-home by nurse/care-giver Makena single-dose launch offers an oppo

  12. Slide 12: CBR: Unlocking the Potential Value of Newborn Stem Cells

    CBR: Unlocking the Potential Value of Newborn Stem Cells Recurring revenue with upside potential: Revenue model: One-time, upfront collection and processing fee On-going annual storage fees Strong brand recognition and customer loyalty 633,000+ units cumulatively stored <1% annual attrition rate Fut

  13. Slide 13: Hematology / Oncology and Hospital

    Hematology / Oncology and Hospital

  14. Slide 14: Feraheme Key Growth Drivers

    Key Growth Drivers Feraheme is indicated for the treatment of iron deficiency anemia (IDA) in adults with chronic kidney disease (CKD) Six Orange Book listed patents, five of which expire in 2020 and one which expires in 20231 Recent Accomplishments and Future Growth Drivers Returned to growth after

  15. Slide 15: Feraheme Growth Opportunities

    Growth Opportunities 1 If regulatory approval is received for broad IDA indication. 2 Global Intravenous (I.V.) Iron Drugs Market Report: 2015 Edition. Initiating head-to-head Phase 3 clinical trial in 1Q16 to evaluate the safety of Feraheme compared to Injectafer®, with potential approval for broad

  16. Slide 16: Feraheme Growth Opportunities

    : Geamag Feraheme Growth Opportunities EXPAND LABEL AND GROW IV IRON MARKET Initiating head-to-head Phase 3 clinical trial in 1Q16 to evaluate the safety of Feraheme compared to Injectafer®, with potential approval for broad IDA indication in 2018.1 4.5 MM patients diagnosed with IDA, many placed on

  17. Slide 17: 2016 Financial Guidance

    2016 Financial Guidance ($ MM) 2016 Guidance1 % Increase over 2015 (midpoint of guidance) Makena sales $310 - $340 +29% Feraheme and MuGard sales $95 - $105 +11% Cord Blood Registry revenue $115 - $1253 +1%2 Total non-GAAP product revenue1 $520 - $570 +42% Non-GAAP adjusted EBITDA1 $255 - $285 +27%

  18. Slide 18: Leverage Commercial Expertise with Acquisitions

    Leverage Commercial Expertise with the Acquisition of Products/Companies that Accelerate Future Growth Strong Financial profile, management team & corporate infrastructure FUTURE PRODUCT Maternal Health Hematology/Oncology, Nephrology & Hospital Consumer marketing expertise FUTURE PRODUCT CBR Commer

  19. Slide 19: 2016 Key Priorities

    2016 Key Priorities Financial and Commercial Drive significant net product sales growth +40% Commercialize single-dose, preservative-free formulation of Makena in 2Q16 Increase non-GAAP adjusted EBITDA to >$255 MM Initiate share repurchase program Product Development Conduct Makena bioequivalence st

  20. Slide 20: AMAG Pharmaceuticals 4Q 2015 Financial Results

    AMAG Pharmaceuticals 4Q 2015 Financial Results February 17, 2016

  21. Slide 21: Appendix

    AMAG Pharmaceuticals Appendix 4Q 2015 Financial Results February 17, 2016

  22. Slide 22: GAAP to Non-GAAP Financials for the Three Months Ended December 31, 2015

    GAAP to Non-GAAP Financials for the Three Months Ended December 31, 2015 Three Months Ended Three Months Ended December 31, 2015 December 31, 2014 GAAP Adjustments Non - GAAP GAAP Adjustments Non - GAAP Revenues: Makena $ 67,356 $ — $ 67,356 $ 2 2,512 $ — $ 22,512 Feraheme/MuGard 23,476 — 23,476 24,

  23. Slide 23: GAAP to Non-GAAP Financials for the Year Ended December 31, 2015

    GAAP to Non-GAAP Financials for the Year Ended December 31, 2015 Twelve Months Ended Twelve Months Ended December 31, 2015 December 31, 2014 GAAP Adjustments Non - GAAP GAAP Adjustments Non - GAAP Revenues: Makena $ 251,615 $ — $ 251,615 $ 22,513 $ — $ 22,513 Feraheme/MuGard 90,201 — 90,201 87,485 —

  24. Slide 24: GAAP to Non-GAAP Footnotes

    GAAP to non-GAAP Financials for the Three Months and Full Year Ended December 31, 2015 7,17 Adding back period write-down of deferred revenue from purchase accounting. 8,18 Eliminate non-cash revenue related to recognition of previously deferred revenue on Takeda agreement. 9,19 Eliminate the follow

  25. Slide 25: 2016 Financial Guidance Reconciliation

    2016 Financial Guidance Reconciliation ($ MM) 2016 Guidance GAAP Net income $11 - $41 CBR deferred revenue purchase accounting adjustments $17 Depreciation & amortization $90 Interest expense, net $72 Provision for income taxes $20 EBITDA $210 - $240 Non-cash inventory step-up $5 Stock-based compens

  26. Slide 26: Share Reconciliation

    Share Reconciliation 1 Convertible notes would be ant-dilutive in this period utilizing the “if-converted” method, which adjusts net income for the after-tax interest expense applicable to the Convertible notes. 2 Reflects the impact of the non-GAAP benefit of the bond hedge and warrants. 3 Reflects

  27. Slide 27: Capitalization

    ($ MM) 4Q15 Cash and cash equivalents $466 Convertible senior notes (2.5%) $200 Term loan facility (4.75%) 346 2023 senior notes (7.875%) 500 Total debt $1,046 Capitalization As of December 31, 2015 ($ MM) 12/31/15 Shares outstanding (millions) 34.7 Net operating loss balance1 $503 1 A portion of th

  28. Slide 28: CBR Non-GAAP Revenue Adjustment

    CBR Non-GAAP Revenue Adjustment Purchase accounting future impact Deferred revenue balance on August 17, 2015 Addback to calculate non-GAAP revenue to be reported in future periods ($ MM) Purchase accounting rules require write-down of closing date deferred revenue on balance sheet at acquisition da

  29. Slide 29: AMAG Pharmaceuticals 4Q 2015 Financial Results

    AMAG Pharmaceuticals 4Q 2015 Financial Results February 17, 2016

  30. Slide 30: AMAG Pharmaceuticals 4Q 2015 Financial Results

    AIVIAG jarmaceuticals 402015 Financial /Results laryil/7 201 ‘A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE PATIENTS’ LIVES

Amag Pharmaceuticals — Q4 2015 Earnings Presentation on 6ix